Here, the authors present a case of a patient with alcohol use disorder who developed an addictive-like consumption of sugary food associated with misuse of his insulin.
In this report, the authors discuss a case of behavioral frontotemporal dementia presenting with catatonia and describe brain functional modifications after drug treatment investigated with PET/MRI.
In this case series, the authors describe a case of delayed ejaculation and a case of premature orgasm and provide an overview of the literature on this topic.
Can dehydration lead to psychosis? Read this unique case of brief psychotic episode related to a medical condition, for which dehydration seemed to be the most likely etiology.
Explore the neurobiological, psychological, psychosocial, and cultural determinants of opioid use disorder and review approaches to integrated, culturally competent care.
Recognition of sex differences can promote a more personalized patient-centered care approach to ensure goals of therapy are achieved among patients prescribed antipsychotics. Read on to find out more.
Here, the authors provide primary care providers a foundation for understanding pediatric hyperkinetic movement disorders, including tips on creation of a differential diagnosis, assessment of risk factors, and guidance on management strategies.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”
MY ACCOUNT